Skip to main content

Table 4 The cross-sectional association between B12 (OR per 1SD increase lnB12) and prevalent albuminuria and RKF in the NHANES 2003–2004 study

From: The association between vitamin B12, albuminuria and reduced kidney function: an observational cohort study

   

Model 1

Model 2

Model 3

 

n

Events (%)1

OR

CI

p-value

OR

CI

p-value

OR

CI

p-value

Entire cohort

          

Albuminuria

4395

764 (13.3)

1.05

0.87-1.27

0.56

1.13

0.88-1.45

0.26

1.16

0.89-1.50

0.26

RKF

4445

489 (7.0)

1.13

0.85-1.51

0.37

1.17

0.85-1.61

0.32

3.06

2.30-4.08

<0.001

Stratified analysis: Albuminuria2

          

Homocysteine < median

2196

277 (11.5)

1.14

0.86-1.51

0.32

1.27

0.88-1.83

0.18

1.24

0.84-1.83

0.26

Homocysteine ≥ median

2197

487 (15.1)

1.05

0.80-1.36

0.72

1.05

0.79-1.40

0.26

1.18

0.88-1.59

0.26

Stratified analysis: RKF2

          

Homocysteine < median

2222

18 (0.7)

0.64

0.15-2.74

0.52

0.63

0.14-2.85

0.52

0.62

0.14-2.76

0.51

Homocysteine ≥ median

2223

471 (13.3)

1.56

1.16-2.09

0.01

1.59

1.16-2.17

0.01

3.46

2.64-4.53

<0.001

  1. Model 1: Age- and sex- adjusted.
  2. Model 2: Multivariable-adjusted: Albuminuria - systolic blood pressure, HDLc, smoking status, hypertension treatment and diabetes.
  3. RKF: diabetes, hypertension and dipstick proteinuria.
  4. Model 3: Multivariable-adjusted + lnhomocysteine.
  5. 1Percentages are weighted to reflect the US population and take into account the multi-stage complex sampling design used to enroll NHANES participants.
  6. 2Stratified by the median homocysteine levels (8.34 μmol/L).